Last reviewed · How we verify
Peginterferon alfa 2
Peginterferon alfa-2 is an interferon that activates the immune system to fight viral infections and certain cancers by binding to interferon-alpha receptors on immune cells.
Peginterferon alfa-2 is an interferon that activates the immune system to fight viral infections and certain cancers by binding to interferon-alpha receptors on immune cells. Used for Chronic hepatitis C, Chronic hepatitis B, Melanoma.
At a glance
| Generic name | Peginterferon alfa 2 |
|---|---|
| Also known as | Pegasys |
| Sponsor | Dr. Conrado Fernandez |
| Drug class | Interferon alpha |
| Target | Interferon-alpha receptor (IFNAR) |
| Modality | Small molecule |
| Therapeutic area | Immunology, Virology, Oncology |
| Phase | FDA-approved |
Mechanism of action
Peginterferon alfa-2 is a pegylated form of interferon-alpha that enhances and prolongs immune activation. It binds to type I interferon receptors on immune cells, stimulating antiviral and antiproliferative responses. The pegylation extends the drug's half-life, allowing for less frequent dosing compared to non-pegylated interferon.
Approved indications
- Chronic hepatitis C
- Chronic hepatitis B
- Melanoma
- Follicular lymphoma
Common side effects
- Flu-like symptoms (fever, chills, fatigue)
- Headache
- Myalgia
- Depression
- Thrombocytopenia
- Neutropenia
- Anemia
Key clinical trials
- A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C (PHASE1)
- Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients (PHASE3)
- A Follow-up Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B (NA)
- Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD) (PHASE2)
- Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection (PHASE2)
- A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B (PHASE3)
- HBsAg Seroclearance in Adults With HBV Related Liver Fibrosis After Receiving Combined Therapy of Peg-IFN and Tenofovir. (PHASE4)
- Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Peginterferon alfa 2 CI brief — competitive landscape report
- Peginterferon alfa 2 updates RSS · CI watch RSS
- Dr. Conrado Fernandez portfolio CI